This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2005 May;20(5):643; author reply 643-4.

doi: 10.1002/mds.20435.

Levodopa in the treatment of Parkinson's disease: current controversies

Manfred Gerlach, Heinz Reichmann, Peter Riederer

PMID: 15732130
DOI: 10.1002/mds.20435

Comment

Levodopa in the treatment of Parkinson's disease: current controversies

Manfred Gerlach et al. Mov Disord. 2005 May.

. 2005 May;20(5):643; author reply 643-4.

doi: 10.1002/mds.20435.

Authors

Manfred Gerlach, Heinz Reichmann, Peter Riederer

PMID: 15732130
DOI: 10.1002/mds.20435

No abstract available

PubMed Disclaimer

Comment on

Levodopa in the treatment of Parkinson's disease: current controversies.
Olanow CW, Agid Y, Mizuno Y, Albanese A, Bonuccelli U, Damier P, De Yebenes J, Gershanik O, Guttman M, Grandas F, Hallett M, Hornykiewicz O, Jenner P, Katzenschlager R, Langston WJ, LeWitt P, Melamed E, Mena MA, Michel PP, Mytilineou C, Obeso JA, Poewe W, Quinn N, Raisman-Vozari R, Rajput AH, Rascol O, Sampaio C, Stocchi F. Olanow CW, et al. Mov Disord. 2004 Sep;19(9):997-1005. doi: 10.1002/mds.20243. Mov Disord. 2004. PMID: 15372588 Review.

Similar articles

Current controversies: levodopa in the treatment of Parkinson's disease.
Sharma JC, Vassallo M, Ross IN. Sharma JC, et al. Mov Disord. 2005 May;20(5):642-3; author reply 643-4. doi: 10.1002/mds.20444. Mov Disord. 2005. PMID: 15732129 No abstract available.
[Pergolide: a useful agonist for the treatment of Parkinson disease].
Bonnet AM, Houeto JL. Bonnet AM, et al. Rev Neurol (Paris). 2002 Jul;158(6-7):744-5. Rev Neurol (Paris). 2002. PMID: 12486908 Clinical Trial. French.
Ropinirole as compared with levodopa in Parkinson's disease.
Hiner BC, Earnhart M. Hiner BC, et al. N Engl J Med. 2000 Sep 21;343(12):884; author reply 885. doi: 10.1056/NEJM200009213431211. N Engl J Med. 2000. PMID: 11001684 No abstract available.
[Pharmacological therapy of complicated Parkinson's disease].
Jiménez-Jiménez FJ, Molina JA. Jiménez-Jiménez FJ, et al. Rev Neurol. 1997 Aug;25 Suppl 2:S170-9. Rev Neurol. 1997. PMID: 9280685 Review. Spanish.
The phenomenology of L-dopa-induced dyskinesias in Parkinson's disease.
Vidailhet M, Bonnet AM, Marconi R, Durif F, Agid Y. Vidailhet M, et al. Mov Disord. 1999;14 Suppl 1:13-8. Mov Disord. 1999. PMID: 10493399 Review. No abstract available.

See all similar articles

Cited by

Development and Differentiation of Midbrain Dopaminergic Neuron: From Bench to Bedside.
Wang M, Ling KH, Tan JJ, Lu CB. Wang M, et al. Cells. 2020 Jun 18;9(6):1489. doi: 10.3390/cells9061489. Cells. 2020. PMID: 32570916 Free PMC article. Review.
The Crucial Roles of Pitx3 in Midbrain Dopaminergic Neuron Development and Parkinson's Disease-Associated Neurodegeneration.
Wang X, Chen X, Liu G, Cai H, Le W. Wang X, et al. Int J Mol Sci. 2023 May 11;24(10):8614. doi: 10.3390/ijms24108614. Int J Mol Sci. 2023. PMID: 37239960 Free PMC article. Review.
Adopting the Rumsfeld approach to understanding the action of levodopa and apomorphine in Parkinson's disease.
Jenner P, Falup-Pecurariu C, Leta V, Verin M, Auffret M, Bhidayasiri R, Weiss D, Borovečki F, Jost WH. Jenner P, et al. J Neural Transm (Vienna). 2023 Nov;130(11):1337-1347. doi: 10.1007/s00702-023-02655-0. Epub 2023 May 20. J Neural Transm (Vienna). 2023. PMID: 37210460 Free PMC article. Review.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Wiley
Medical
- MedlinePlus Health Information